DiamondPeak Holdings Corp. (DPHCU) Files for $250M SPAC IPO
by Kristi Marvin on 2019-01-18 at 1:58pm

This morning, DiamondPeak Holdings Corp. (DPHCU) filed for a $250 million SPAC IPO focused on the real estate sector.  DiamondPeak will be led by David Hamamoto, the former founder of the Northstar Companies, which was sold to Colony Capital (NYSE: CLNY) in January of 2017. Mr. Hamamoto will be the Chairman and CEO of DiamondPeak.

Rounding out the team, however, are three former Lehman Brother’s Real Estate veterans.  Kyriakos Mihalitsis, the CFO of DiamondPeak, joined Lehman Brother Real Estate Partners in 2006. Mark Walsh, a Director, headed Lehman Brothers’ Global Real Estate Group and served as Global Co-Head of Lehman Brothers Real Estate Private Equity, before founding SilverPeak in 2010 (a multi-strategy investment platform). And finally, Steven Hash, a Director Nominee, was Global Head of Real Estate Investment Banking from 2006 to 2012 and Chief Operating Officer of Global Investment Banking from 2008 to 2011, among other roles while at Lehman (and it’s successor, Barclay’s).

Now, hindsight is 20/20, and it may seem incredulous now, but very few people saw the real estate collapse coming back then, or at least how significant it would be and how it would precipitate the financial crisis.  So yes, having the words “Lehman” and “Real Estate” might sound kind of scary on a CV, but if you read The Big Short (or saw the movie), there were really only a handful of people that were able to actually connect the dots while there was still time to correct anything.  Regardless, with experience (and maybe more so with bad experiences) comes knowledge and what not do in the next go around.

Looking at the terms, this structure is very similar to RMG Acquisition Corp., another Deutsche Bank deal.  Even the addition of the Crescent Term uses the threshold of $9.20, just like RMG does. However, the SPAC market remains tight. We won’t know if it’s beginning to loosen until we see a few deals price, so it remains to be seen if DiamondPeak needs to make some adjustments to terms.  However, they did remove the delaying amendment on this first filing.  Which means, come Feb. 7th, this deal could potentially price.   We’ll keep an eye out for any changes.

Summary of terms below:

diamondpeak terms

Deutsche Bank is sole bookrunning manager.
Ellenoff Grossman & Schole LLP, and Ropes & Gray LLP, are issuer’s counsel and underwriter’s counsel, respectively.

 

Recent Posts
by Nicholas Alan Clayton on 2024-04-18 at 11:50am

AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...

by Nicholas Alan Clayton on 2024-04-18 at 7:57am

At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...

by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved